Navigation Links
Researchers Find Link Between Organ Transplants, Cancer
Date:7/16/2008

Immune-suppressing drugs may trigger protein that boosts tumor growth, study finds

WEDNESDAY, July 16 (HealthDay News) -- Anti-rejection drugs given after organ transplants may be the reason why 15 percent to 20 percent of individuals who receive such transplants have a higher risk of developing cancer within the next decade.

The good news is that targeted therapies could diminish the risk, said Harvard researchers reporting in the July 15 issue of Cancer Research.

The tumors themselves may have already existed before the transplant procedure or they may be a return of an old cancer. An immune system dampened by immunosuppressive drugs could make it easier for both scenarios to take place. On the other hand, a virus introduced from the donor organ may have precipitated the cancer, the researchers said.

And heightened production of vascular endothelial growth factor (VEGF) after the transplant may also be a factor. While this protein facilitates essential blood flow to the new organ, it can also promote the formation of new blood vessels which feed tumor growth, according to the researchers.

"It may be that anti-VEGF agents given judiciously after transplantation can reduce future cancer occurrence," said study senior author Soumitro Pal, assistant professor at Harvard Medical School's Transplantation Research Center at Children's Hospital in Boston, in a news release from the American Association for Cancer Research. "... Once the organ has stabilized, it may be possible to lower the level of VEGF expression to prevent tumor growth. We would need to figure out how to balance benefit and risk to keep cancer at bay."

Pal and his colleagues implanted human kidney cancer cells into mice, then gave the rodents cyclosporine, an immunosuppressant drug often used after transplants. Mice that received the drug grew tumors at a faster rate than mice left untreated.

But the researchers also found a potential solution to the problem: Giving targeted anti-VEGF therapy reduced the pace of growth.

Cyclosporine seems to promote the growth of cancer by activating different forms of protein kinase C, which, in turn, stimulates VEGF production, the researchers said.

More information

For more on organ and tissue donation, visit organdonor.gov.



-- HealthDay Staff



SOURCE: American Association for Cancer Research, news release, July 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Tufts researchers discover link between DNA palindromes and disease
2. Researchers hone technique to KO pediatric brain tumors
3. Researchers link Huntingtons disease to overactive immune response in the brain
4. Researchers: Program discourages HIV transmission in Russia
5. Stanford Bio-X researchers use needle-thin probe to get first look at working muscle fiber
6. Researchers design model for automated, wearable artificial kidney
7. Researchers Gather to Address New Tools in Development for Breast Cancer Detection
8. Some drugs increase risk of falling: UNC researchers
9. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
10. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
11. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: